Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Exploring Partnerships As Alternative To REMS Mandate For Opioid Education

Executive Summary

The US FDA is continuing to think through mechanisms to make opioid prescriber education mandatory – either separate from or in addition to relying on its REMS authority. 

You may also be interested in...



The Opioid Is In The Mail?

The US Postal Service is suddenly a key cog in the US public health infrastructure – but don’t expect FDA to mandate mail-back packaging on opioids right away.

US FDA May Seek Legal Authority To Require Superiority Tests For Future Opioids

Commissioner Califf testifies at budget appropriations hearing that the agency may ask Congress to give it authority to require a new opioid drug application to show superiority to opioids on the market.

Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics

Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel